logo-loader
viewQ BioMed Inc.

Q BioMed CEO sees significant capital funding for next 3 years

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive announced that its technology partner, Mannin Research Inc, has received a $7.5 million grant from the German state of Saxony to fund the development of its glaucoma therapies.

Corin talked about how the two partners plan to accelerate the pre-clinical efforts of its two approaches to prevent glaucoma.

Quick facts: Q BioMed Inc.

Price: 2.12 USD

OTCMKTS:QBIO
Market: OTCQB
Market Cap: $44.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed infuses first patient with its FDA-approved cancer...

Q BioMed Inc. (OTCQB:QBIO) CEO Denis Corin tells Proactive the New York-based biotech company, has dosed its first patient in a commercial setting with its FDA approved non-opioid drug Strontium89 for patients with pain from metastatic bone cancer. Corin says the company is working on making...

3 weeks, 5 days ago

2 min read